Assessing Cancer Patients' Exposure to Treatment Misinformation.

Understanding when and how patients encounter cancer treatment misinformation (CTM) is essential for developing innovative strategies to combat its spread. However, a major challenge in CTM research is the lack of a reliable and valid tool to assess exposure to misinformation. This study aimed to evaluate patients' exposure to CTM through the exposure to cancer treatment misinformation (ECTM) survey. CTM was operationalized as including unproven or disproven cancer treatments, foregoing recommended conventional cancer treatments, and acceptance of myths and misconceptions directly or indirectly related to cancer care. A total of 110 participants with a cancer diagnosis completed the survey. They were asked to identify non-evidence-based potential cancer treatments that they had heard of from a provided list. Overall, 93% (n = 102) reported exposure to at least one form of CTM. Most (79%) had encountered at least one cancer myth or misconception identified by the U.S. National Cancer Institute. Passive exposure to CTM, rather than active information-seeking, was more commonly reported. Friends and family were cited by participants as the most common source of CTM. These findings underscore the utility of the ECTM survey in capturing multiple dimensions of CTM exposure, including source, exposure type (seeking versus scanning), categorizing CTM types, and whether patients engage oncologists in discussions about the CTM they encounter. Future research should focus on validating the ECTM across diverse populations, exploring patient-oncologist communication about CTM, identifying patterns of CTM exposure, and using the tool as an outcome measure in interventions designed to decrease misinformation exposure.